<DOC>
	<DOCNO>NCT01803646</DOCNO>
	<brief_summary>The purpose research study test safety effectiveness study drug , AM-101 . AM-101 test treatment tinnitus start result injury inner ear due middle ear inflammation ( otitis medium ) . Subjects tinnitus take part study , tinnitus start within last 3 month .</brief_summary>
	<brief_title>AM-101 Treatment Acute Tinnitus 2</brief_title>
	<detailed_description>This phase III study assess drug 's safety aim demonstrate efficacy repeat intratymanic AM-101 injection treatment acute peripheral tinnitus ( 3 month onset ) .</detailed_description>
	<mesh_term>Tinnitus</mesh_term>
	<criteria>1 . Persistent subjective peripheral tinnitus ( unilateral bilateral ) follow traumatic cochlear injury ( acute acoustic trauma , blast trauma , middle ear surgery , inner ear barotrauma , tympanic membrane trauma ) otitis medium onset longer 3 month prior randomization 2 . Age ≥ 18 year ≤ 75 year ( ≥ 14 year ≤ 75 year select site ) ; 3 . Negative pregnancy test ( woman childbearing potential ) ; 4 . Willing able use adequate hearing protection , respectively refrain engaging activity work involve loud noise exposure sufficient hearing protection possible ensure ; 5 . Willing able protect ear canal middle ear water exposure long tympanic membrane fully close . Other protocoldefined inclusion criterion may apply . 1 . Fluctuating tinnitus ; 2 . Intermittent tinnitus ; 3 . Tinnitus result traumatic head neck injury ; 4 . Presence chronic tinnitus ; 5 . Meniere 's Disease , history endolymphatic hydrops , history fluctuate hearing loss ; 6 . History repeat idiopathic sudden sensorineural hearing loss history acoustic neuroma ; 7 . Ongoing acute chronic otitis medium otitis externa ; 8 . Other treatment tinnitus study duration ; 9 . Known hypersensitivity , allergy intolerance study medication history severe , abnormal drug reaction ; 10 . Women breastfeed , pregnant planning become pregnant study ; 11 . Women childbearing potential unwilling unable practice contraception , hormonal contraceptive , double barrier , sexual abstinence intercourse partner vasectomise least three month ; 12 . Concurrent participation another clinical study participation another clinical study within 30 day prior randomization . Other protocoldefined exclusion criterion may apply .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>July 2016</verification_date>
</DOC>